Rhythm Pharmaceuticals (RYTM) was raised to a "buy" recommendation by an influential sell-side firm Monday. Shares of this commercial-stage biopharmaceutical company have soared sharply in recent weeks so we want to see how we should proceed.




Rhythm Pharmaceuticals (RYTM) was raised to a "buy" recommendation by an influential sell-side firm Monday. Shares of this commercial-stage biopharmaceutical company have soared sharply in recent weeks so we want to see how we should proceed.
The semiconductor giant went from breakdown to breakout in a matter of days, which makes it an interesting trade opportunity.
As we check the charts, I have two price targets.
Let's look at the risks to the sector and what could be a safe buy.
About 90% of stocks are still struggling, but many market players are celebrating.
When investors get giddy right at the peak of a market move, it's time to pay attention.
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login